G
Geert R. D'Haens
Researcher at University of Amsterdam
Publications - 661
Citations - 35027
Geert R. D'Haens is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 70, co-authored 466 publications receiving 28558 citations. Previous affiliations of Geert R. D'Haens include Academic Medical Center & Robarts Research Institute.
Papers
More filters
Journal ArticleDOI
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Eric Van Cutsem,Claus Henning Köhne,Erika Hitre,J. Zaluski,Chung Rong Chang Chien,A. Makhson,Geert R. D'Haens,Tamás Pintér,Robert Lim,György Bodoky,Jae Kyung Roh,Gunnar Folprecht,Paul Ruff,Christopher Stroh,Sabine Tejpar,Michael Schlichting,Johannes Nippgen,Philippe Rougier +17 more
TL;DR: In this paper, the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer was investigated.
Journal ArticleDOI
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
Geert R. D'Haens,Filip Baert,Gert Van Assche,Philip Caenepeel,Philippe Vergauwe,Hans Tuynman,Martine De Vos,Sander J. H. van Deventer,Larry Stitt,Allan Donner,Allan Donner,Severine Vermeire,Frank J. Van de Mierop,Jean-Charles R Coche,Janneke van der Woude,Thomas Ochsenkühn,Ad A. van Bodegraven,Philippe Van Hootegem,Guy Lambrecht,Fazia Mana,Paul Rutgeerts,Brian G. Feagan,Brian G. Feagan,Daniel W. Hommes +23 more
TL;DR: Combined immunosuppression was more effective than conventional management for induction of remission and reduction of corticosteroid use in patients who had been recently diagnosed with Crohn's disease.
Journal ArticleDOI
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn,Chinyu Su,Bruce E. Sands,Geert R. D'Haens,Severine Vermeire,Stefan Schreiber,Silvio Danese,Brian G. Feagan,Walter Reinisch,Wojciech Niezychowski,Gary S. Friedman,Nervin Lawendy,Dahong Yu,Deborah A Woodworth,Arnab Mukherjee,Haiying Zhang,Paul J. Healey,Julián Panés +17 more
TL;DR: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo and was associated with increased lipid levels.
Journal ArticleDOI
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn,Gert Van Assche,Walter Reinisch,Jean-Frederic Colombel,Geert R. D'Haens,Douglas C. Wolf,Martina Kron,Mary Beth Tighe,Andreas Lazar,Roopal Thakkar +9 more
TL;DR: Adalimumab was safe and more effective than placebo in inducing and maintaining clinical remission in patients with moderate-to-severe ulcerative colitis who did not have an adequate response to conventional therapy with steroids or immunosuppressants.
Journal ArticleDOI
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations
Gert Van Assche,Axel Dignass,Walter Reinisch,C. Janneke van der Woude,Andreas Sturm,Martine De Vos,Mario Guslandi,Bas Oldenburg,Iris Dotan,Philippe Marteau,Alessandro Ardizzone,Daniel C. Baumgart,Geert R. D'Haens,Paolo Gionchetti,Francisco Portela,Boris Vucelić,Johan D. Söderholm,Johanna C. Escher,Sibylle Koletzko,Kaija-Leena Kolho,Milan Lukas,Christian Mottet,Herbert Tilg,Severine Vermeire,F. Carbonnel,Andrew T. Cole,Gottfried Novacek,Max Reinshagen,Epameinondas V. Tsianos,Klaus Herrlinger,Yoram Bouhnik,Ralf Kiesslich,Eduard F. Stange,Simon Travis,James O. Lindsay +34 more
TL;DR: The aim of this Consensus was therefore critically to evaluate the optimal strategies for the management of post-operative recurrence in CD.